Skip to main content
. 2016 Jul 7;5(10):1307–1318. doi: 10.5966/sctm.2015-0337

Figure 5.

Figure 5.

Early administration of MSCs protects lungs from bleomycin-induced fibrosis. Lungs were harvested on D28 of the bleomycin model for histological assessment. (A): Representative images of H&E (upper panel) and trichrome-stained (lower panel) lung sections (10×) show collagen deposition and alveolar damage. Scale bar = 200 μm. (B): Fibrotic score was significantly reduced when MSCs were administered on D0 but not on D9. (C): mRNA expression of IL-1β was measured in the lungs using qPCR on D21 of the bleomycin study. IL-1β mRNA expression was reduced when MSCs were administered on D0 but not day D9. (D): HGF mRNA expression was measured in the lungs using quantitative polymerase chain reaction. HGF mRNA expression was enhanced when MSCs were administered on D0 but not on D9. n = 5. ∗, p < .05; ∗∗, p < .01; ∗∗∗, p < .001. Abbreviations: D, day; H&E, hematoxylin and eosin; HGF, hepatocyte growth factor; IL-1β, interleukin-1β; IN, intranasal; IV, intravenous; MSC, mesenchymal stromal cell; PBS, phosphate-buffered saline.